GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5705 Q94 hydrochlorideTarget: PAR receptorSummary: PAR1 negative allosteric modulator -
B5706 COR 170Summary: inverse agonist of CB2 receptors -
B5710 BETPSummary: glucagon-like peptide 1 (GLP-1) receptor modulator -
B5711 VUF 11207 fumarateSummary: ACKR3 (CXCR7) chemokine receptor agonist -
B5717 Org 37684Summary: 5-HT2 receptors agonist -
B5726 PF 04418948Summary: EP2 receptor antagonist -
B5744 H2L 5765834Summary: lysophosphatidic acid receptors antagonist -
B5748 H2L5186303Summary: lysophosphatidic acid 2 (LPA2) receptor antagonist -
B5749 TC-G 1001Summary: GPR35 agonist -
B5751 LUF 6283Summary: partial agonist of hydroxycarboxylic acid receptor 2 (HCA2)

